AIRSUPRA Dosing
AIRSUPRA is dosed as 2 inhalations (180 mcg albuterol/160 mcg budesonide total) taken as needed for asthma symptoms, with a maximum of 6 doses (12 inhalations) per 24-hour period. 1
Specific Dosing Instructions
Standard Dose:
- Each dose = 2 actuations of the inhaler
- Each actuation delivers albuterol 90 mcg + budesonide 80 mcg
- Total per dose: albuterol 180 mcg + budesonide 160 mcg
- Use as needed when asthma symptoms occur 1
Maximum Daily Limit:
- Do not exceed 6 doses (12 inhalations) in any 24-hour period 1
Priming Requirements
Initial Priming (First Use):
- Release 4 sprays into the air away from face
- Shake well before each spray 1
Re-Priming Required When:
- Inhaler not used for more than 7 days
- Inhaler is dropped
- After cleaning the inhaler
- Re-prime with 2 sprays into the air away from face, shaking well before each spray 1
Dose Counter and Disposal
The inhaler has an attached dose indicator that:
- Moves after every actuation
- Shows remaining inhalations
- Changes to yellow when nearing end
- Discard when pointer reaches zero 1
Clinical Context and Evidence
This as-needed dosing strategy represents a paradigm shift from traditional SABA-only rescue therapy. The MANDALA trial demonstrated that as-needed albuterol-budesonide reduced severe exacerbation risk by 26% compared to albuterol alone in patients with moderate-to-severe asthma (hazard ratio 0.74,95% CI 0.62-0.89, P=0.001) 2. More recently, the BATURA trial showed similar benefits in mild asthma, with a 47% reduction in severe exacerbations (hazard ratio 0.53,95% CI 0.39-0.73) 3.
Important Clinical Points:
- AIRSUPRA is FDA-approved for patients 18 years and older 1
- Patients should continue their maintenance ICS therapy if prescribed
- Mean daily use in clinical trials was approximately 2.6 inhalations per day, with high daily use (≥8 inhalations/day) being rare 4
- The combination addresses both bronchoconstriction and inflammation simultaneously, unlike SABA-only therapy
Key Safety Considerations
When to Seek Medical Evaluation:
- If symptoms persist after using AIRSUPRA
- If more doses than usual are needed
- These may indicate asthma destabilization requiring treatment adjustment 1
Contraindications:
- History of hypersensitivity to albuterol, budesonide, or any excipients 1
The as-needed dosing flexibility allows patients to adjust use based on symptom burden while maintaining anti-inflammatory coverage during periods of increased symptoms, which is when exacerbation risk is highest. This represents a significant advancement over the traditional approach of separating rescue (SABA) and controller (ICS) therapies into different inhalers 5.